Neutech Group strategically expands wellness tourism business resources, accelerating the development of new ecosystem of education, healthcare, wellness and mind tour
HONG KONG, May 26, 2025 /PRNewswire/ -- On 20 May 2025, Neutech Group Limited ("Neutech Group" or the "Group"; stock code: 9616.HK) announced the acquisition of partial equity interest in Xikang Wellness & Resorts, which will further strengthen the Group's integration of resources in the "wellness tourism" business, support the specialized development of elderly education, and expand the practical...
Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safety and tolerability as a monotherapy in heavily pre-treated non-small cell lung cancer (NSCLC) patients with EGFR-mutations...
Esaote: The new MyLab™Heron ultrasound scanner for veterinary physicians had its world premiere at the SCIVAC Rimini 2025 Congress
GENOA, Italy, May 26, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, has presented the world premiere of the new MyLab™Heron ultrasound system at the Congress organized in Rimini from May 23 to 25 May by SCIVAC, the largest Veterinary Scientific Society in Italy,...
VUNO Showcases DeepCARS® at AACN NTI 2025, Highlighting AI-Driven Cardiac Arrest Risk Prediction
– Company engages U.S. critical care professionals with data-driven early warning solution MARLBOROUGH, Mass., May 26, 2025 /PRNewswire/ -- VUNO, a global medical AI company, presented its flagship solution VUNO Med®–DeepCARS® at the 2025 National Teaching Institute & Critical Care Exposition (NTI), hosted by the American Association of Critical-Care Nurses (AACN), from May 19–21 at the Ernest N. Morial...
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of Hepatocellular Carcinoma (HCC). Irpagratinib is the first therapeutic agent...
Chula Researchers Culture “Global-Warming Resistant Corals” for the Survival of Marine Ecosystems
BANGKOK, May 26, 2025 /PRNewswire/ -- Researchers at Chulalongkorn University's Aquatic Resources Research Institute have developed innovative methods to help corals adapt to global warming. Through artificial insemination and raising corals in high-temperature environments from birth, they aim to cultivate corals capable of withstanding rising sea temperatures. In addition, they have introduced cryopreservation techniques to store coral sperm cells for...
World’s First — XellSmart’s Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
SUZHOU, China, May 26, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for a Phase I clinical trial, to treat spinal cord injury (SCI) — a...
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor...
EDAN Highlights Commitment to Global Health at GHF 2025 Satellite Symposium, a Side Event of the World Health Assembly
GENEVA, May 25, 2025 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global medical device company, participated in the Geneva Health Forum (GHF) 2025 Satellite Symposium, held as a side event of the World Health Assembly (WHA). Titled "China's Medical Technology Innovation and Its Implementation for Global Health," the event...
Mindray Debuts Next-Generation BeneVision V Series Patient Monitoring System at Euroanaesthesia 2025
SHENZHEN, China, May 25, 2025 /PRNewswire/ -- Mindray (SZSE: 300760), a leading global developer of healthcare technologies, launched its BeneVision V Series patient monitoring solution at Euroanaesthesia 2025 in Lisbon. Powered by a robust new hardware platform, this advanced system provides industry-first innovations in ultrasound-integrated hemodynamic assessment and cable-lite patient monitoring workflow, redefining the bedside monitor as a dynamic hub of...
